EMA accepted marketing authorization app for Cevira by Asieris; collaboration with Photocure.

Norwegian company Photocure ASA, specializing in bladder cancer solutions, revealed that its collaborator Asieris Pharmaceuticals (SSE: 688176) has reported the submission of a marketing authorization application (MAA) for Cevira® (APL-1702) aimed at treating high-grade conditions. The announcement was made on Feb. 27, 2026. The development signifies a significant move in the field of bladder cancer treatment.